Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [I]

ABSTRACT: The immune system is active in the tumor microenvironment (TME) of epithelial ovarian cancer (EOC) and carries both effector and suppressive functions. We profiled biomarker expression on serial biological specimens collected during intraperitoneal (IP) chemotherapy to better define treatment-induced tumor involution.

ORGANISM(S): Homo sapiens

PROVIDER: GSE217175 | GEO | 2023/06/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [III]

Project description:The immune system is active in the tumor microenvironment (TME) of epithelial ovarian cancer (EOC) and carries both effector and suppressive functions. We profiled biomarker expression on serial biological specimens collected during intraperitoneal (IP) chemotherapy to better define treatment-induced tumor involution.

2023-06-02 | GSE217178 | GEO

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [II]

2023-06-02 | GSE217177 | GEO

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-06-02 | GSE217179 | GEO

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer

Project description:Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer

| PRJNA897854 | ENA

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [III]

Project description:Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [III]

| PRJNA897859 | ENA

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [I]

Project description:Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [I]

| PRJNA897856 | ENA

Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [II]

Project description:Serial Immune Profiling During Intraperitoneal Chemotherapy Shows Changes in Loco-regional Immunity in Ovarian Cancer [II]

| PRJNA897858 | ENA

Gene Expression Profiling Reveals Novel Candidate Markers of Ovarian Carcinoma Intraperitoneal Metastasis

Project description:Epithelial ovarian cancer (EOC) has the highest mortality among gynecological carcinomas. The lack of specific markers for prognostic determination of EOC progression hinders the search for novel effective therapies. The aim of the present study was (i) to explore differences in expressions of ATP-binding cassette and solute carrier transporter genes, genes associated with drug metabolism and cell cycle regulation between control ovarian tissues, primary epithelial ovarian carcinomas (EOC) and intraperitoneal EOC metastases; (ii) to investigate associations of gene expression level with prognosis of patients with intraperitoneal metastases.

2017-09-01 | GSE102180 | GEO

Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma.

Project description:ObjectiveThe recommended first-line treatment for low-tumor-burden ACC (stage IVa ACC) not amenable to radical resection is mitotane in association with loco-regional treatments (LRs). The aim of this study was to determine the patient population that would benefit the most from LR.Materials and methodsThis retrospective monocentric expert center chart review study was performed from 2008 to 2021 and included stage IVa patients (≤2 tumoral organs) treated with LR (either radiotherapy, surgery, or interventional radiology). The primary endpoint was disease control (DC). Correlations between DC, time to systemic chemotherapy (TTC), overall survival (OS), and tumor characteristics were analyzed using Kaplan-Meier survival analysis and Cox's proportional hazards regression model for multivariate analysis.ResultsThirty-four women (57%) and 26 men with a median age of 48.1 years (IQR: 38.3-59.8) were included. One hundred and nine LRs were performed, with a median of 2 (IQR: 1-3) per patient. DC was achieved in 40 out of 60 patients (66.7%). Patients with DC had a significantly longer TTC (HR: 0.27, p < 0.001) and OS (HR: 0.22, p < 0.001). Patients with less than or equal to 5 metastases (HR: 6.15 (95% CI: 1.88-20.0), p = 0.002) or a maximum metastasis diameter below 3 cm had higher rates of DC (HR: 3.78 (95% CI: 1.09-13.14), p = 0.035).Conclusionstage IVa ACC patients with ≤5 metastases or a maximum metastasis diameter below 3 cm had favorable responses to LR. We propose the name oligometastatic ACC for this subgroup of patients.

| S-EPMC9179919 | biostudies-literature

Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery.

Project description:BackgroundLoco-regional recurrences (LRR) following breast-conserving surgery (BCS) remain a heterogeneous class of disease that has significant variation in its biological behavior and prognosis.MethodsTo delineate the spatiotemporal patterns of LRR after BCS, we analyzed the data of 4325 patients treated with BCS from 2006 to 2016. Clinico-pathological and treatment specific factors were analyzed using the Cox proportional hazards model to identify factors predictive for LRR events. Recurrence patterns were scrutinized based on recurrence type and recurrence-free interval (RFI). Annual recurrence rates (ARR) were compared according to recurrence type and molecular subtype.ResultsWith a median follow-up of 66 months, 120 (2.8%) LRRs were recorded as the first site of failure. Age, pathologic stage, and molecular subtype were identified as predictors of LRR. The major recurrence type was ipsilateral breast tumor recurrence, which mainly (83.6%) occurred ≤5y post surgery. In the overall population, ARR curves showed that relapse peaked in the first 2.5 years. Patients with regional nodal recurrence, shorter RFI, and synchronous distant metastasis were associated with a poorer prognosis. HER2-positive disease had a higher rate of LRR events, more likely to have in-breast recurrence, and had an earlier relapse peak in the first 2 years after surgery.ConclusionsLRR risk following BCS is generally low in Chinese ethnicity. Different recurrence patterns after BCS were related to distinct clinical outcomes. Management of LRR should be largely individualized and tailored to the extent of disease, the molecular profile of the recurrence, and to baseline clinical variables.

| S-EPMC8435899 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data